Ociated to its cancerogenic role was confirmed. For this reason, further

Ociated to its cancerogenic role was confirmed. For this reason, further studies should be done to explore this cancerogenic role of this parasite in human populations considering different factors: 1.The oocyst stage, a common contaminant in surface water world wide is resistant to disinfection with chlorine applied in drinking water treatment plants at standard concentrations [23]. 2. Different evidences show that low challenge of Cryptosporidium oocyst is infective to healthy humans. For instance, a mathematical model based on data from the Milwaukee outbreak suggested that some individuals developed cryptosporidiosis following the ingestion of only one oocyst [24]. Data from another study among healthy adults without evidence of past cryptosporidiosis showed that a low dose of C. parvum oocysts was sufficient to cause infection [5]. 3. A study reported that colon squamous cell carcinoma risk was significantly elevated among AIDS patients who had cryptosporidiosis [25]. Furthermore, a recent epidemiological study in Poland reported a frequency of 12.6 of cryptosporidiosis in patients with colorectal cancer [26].Supporting InformationTable S1 Normalized quantification of parasites in ileocaecal region of mice inoculated with different oocysts doses and euthanatized at different times post-infection. (DOC)AcknowledgmentsThe authors thank Stephanie La Carbona and Catherine Cazeaux for ?providing the amplification reaction mixture conditions for the Cryptosporidium qPCR assay as well as the standard DNA plasmid developed in the framework of the ANR-09-ALIA-009 project and Lobna Gaayeb for her helpful and insightful comments.Author ContributionsConceived and designed the experiments: SB KG MC EDC CC VC GC. Performed the experiments: SB KG SG AM TC BD GC. Analyzed the data: SB KG SG AM TC MC PG EV EDC CC VC GC. Contributed reagents/materials/analysis tools: AM TC PG EV CC. Wrote the paper: SB KG EDC CC VC GC.Adenocarcinoma Induced by Low Doses of C. parvum
Platinum-based combination chemotherapy is the standard firstline treatment for advanced stage epithelial ovarian carcinoma (EOC). The tumors are considered “platinum sensitive” if the clinical progression-free interval is more than 6 months, but approximately 20 to 30 of patients progress or their tumors rapidly become resistant to this treatment [1]. These patients with intrinsic chemoresistance who experience a recurrence within 6 EPZ-5676 site months gain little benefit from standard treatment. There is also evidence suggesting that the longer the interval until recurrence, the better the response rate to subsequent chemotherapy [2]. Therefore, chemoresistance for ovarian cancers may be present atthe outset of treatment (intrinsic resistance) or may develop during treatment (acquired resistance). Currently, chemoresistance of EOC can only be determined retrospectively after patients have experienced the burden and toxicity of ineffective therapy. Therefore, identification of MedChemExpress JNJ-42756493 characteristic molecular biomarkers 1379592 related to intrinsic chemoresistance in EOC may lead to individually customized therapeutics and improvement of outcomes since standard chemotherapy affords them very little benefit. Several recent studies have used gene microarrays to identify distinct gene expression in intrinsic chemoresistant ovarian cancer patients on different platforms, such as nylon cDNA arrays, Affymetrix chips and Agilent oligonucleotide microarrays [3,4].Biomarkers for Chemoresistant Ovarian CancerThese studie.Ociated to its cancerogenic role was confirmed. For this reason, further studies should be done to explore this cancerogenic role of this parasite in human populations considering different factors: 1.The oocyst stage, a common contaminant in surface water world wide is resistant to disinfection with chlorine applied in drinking water treatment plants at standard concentrations [23]. 2. Different evidences show that low challenge of Cryptosporidium oocyst is infective to healthy humans. For instance, a mathematical model based on data from the Milwaukee outbreak suggested that some individuals developed cryptosporidiosis following the ingestion of only one oocyst [24]. Data from another study among healthy adults without evidence of past cryptosporidiosis showed that a low dose of C. parvum oocysts was sufficient to cause infection [5]. 3. A study reported that colon squamous cell carcinoma risk was significantly elevated among AIDS patients who had cryptosporidiosis [25]. Furthermore, a recent epidemiological study in Poland reported a frequency of 12.6 of cryptosporidiosis in patients with colorectal cancer [26].Supporting InformationTable S1 Normalized quantification of parasites in ileocaecal region of mice inoculated with different oocysts doses and euthanatized at different times post-infection. (DOC)AcknowledgmentsThe authors thank Stephanie La Carbona and Catherine Cazeaux for ?providing the amplification reaction mixture conditions for the Cryptosporidium qPCR assay as well as the standard DNA plasmid developed in the framework of the ANR-09-ALIA-009 project and Lobna Gaayeb for her helpful and insightful comments.Author ContributionsConceived and designed the experiments: SB KG MC EDC CC VC GC. Performed the experiments: SB KG SG AM TC BD GC. Analyzed the data: SB KG SG AM TC MC PG EV EDC CC VC GC. Contributed reagents/materials/analysis tools: AM TC PG EV CC. Wrote the paper: SB KG EDC CC VC GC.Adenocarcinoma Induced by Low Doses of C. parvum
Platinum-based combination chemotherapy is the standard firstline treatment for advanced stage epithelial ovarian carcinoma (EOC). The tumors are considered “platinum sensitive” if the clinical progression-free interval is more than 6 months, but approximately 20 to 30 of patients progress or their tumors rapidly become resistant to this treatment [1]. These patients with intrinsic chemoresistance who experience a recurrence within 6 months gain little benefit from standard treatment. There is also evidence suggesting that the longer the interval until recurrence, the better the response rate to subsequent chemotherapy [2]. Therefore, chemoresistance for ovarian cancers may be present atthe outset of treatment (intrinsic resistance) or may develop during treatment (acquired resistance). Currently, chemoresistance of EOC can only be determined retrospectively after patients have experienced the burden and toxicity of ineffective therapy. Therefore, identification of characteristic molecular biomarkers 1379592 related to intrinsic chemoresistance in EOC may lead to individually customized therapeutics and improvement of outcomes since standard chemotherapy affords them very little benefit. Several recent studies have used gene microarrays to identify distinct gene expression in intrinsic chemoresistant ovarian cancer patients on different platforms, such as nylon cDNA arrays, Affymetrix chips and Agilent oligonucleotide microarrays [3,4].Biomarkers for Chemoresistant Ovarian CancerThese studie.